Novo to present 44 abstracts at EASD 2026 including Wegovy pill real-world data

Novo said it will present 44 abstracts at the EASD 2026 diabetes meeting in Milan from 28 September to 2 October, covering semaglutide, CagriSema and zenagamtide. Highlights include real-world OCTANE data on the Wegovy pill, new Wegovy 7.2 mg and Ozempic 2.0 mg analyses, and CagriSema data on appetite, brain responses and body composition. Novo scheduled a virtual press briefing for 30 September. The company noted accepted abstracts contain preliminary data.

• EASD 2026 in Milan, 28 September to 2 October 2026
• 44 abstracts across semaglutide, CagriSema and zenagamtide
• Real-world OCTANE data on the Wegovy pill, including treatment switching
• Virtual press briefing on 30 September 2026
• Accepted abstracts contain preliminary data that may change